After the closing bell yesterday, Positron announced that it has displayed their Pulse CDC Spect imaging system and introduced their new dedicated Cardiac PET system at the annual meeting of the American Society of Nuclear Cardiology. The PET system is expected to receive FDA approval next spring.
Market research has indicated that the cardiologist market would readily move to compliment their molecular imaging offering by adding Positron’s cost effective Attrius system. Positron is expecting considerable demand for their product since they are the only ones offering an all new PET only molecular imaging system for less than $600,000.
Positron Corporation’s President, Joseph Oliverio, stated, “The American Society of Nuclear Cardiology meeting confirmed our internal market research. We strongly believe that we are in a great position to be the leader in the rapidly expanding market of Cardiac PET. We will be the only company that is focused on bringing to market an affordable dedicated cardiac PET scanner with superior technology and disease focused software. We anticipate receiving our 510k FDA approval in spring of 2008.”
Let us hear your thoughts below: